Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.
about
Nutrient deprivation induces α-synuclein aggregation through endoplasmic reticulum stress response and SREBP2 pathwayMolecular determinants of α-synuclein mutants' oligomerization and membrane interactionsNovel subcellular localization for α-synuclein: possible functional consequencesDysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseasesParkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synucleinSIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesisLipid pathway alterations in Parkinson's disease primary visual cortexMechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.Cholesterol in the Pathogenesis of Alzheimer's, Parkinson's Diseases and Autism: Link to Synaptic DysfunctionBeclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseasesReducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models.Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.Statin use and Parkinson's disease in Denmark.Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseasesSerum cholesterol and nigrostriatal R2* values in Parkinson's disease.GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein.Prospects of statins in Parkinson diseaseStatins, plasma cholesterol, and risk of Parkinson's disease: a prospective studyLovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.Statin adherence and the risk of Parkinson's disease: A population-based cohort study.α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.alpha-Synuclein: a therapeutic target for Parkinson's disease?Role of synucleins in Alzheimer's disease.Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells.Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain.Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.Pharmacological therapy in Parkinson's disease: focus on neuroprotection.Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review.An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brainThe ongoing pursuit of neuroprotective therapies in Parkinson disease.Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease.Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line.Pleiotropic effects of statins: new therapeutic targets in drug design.Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.Can Cholesterol Metabolism Modulation Affect Brain Function and Behavior?Potential Modes of Intercellular α-Synuclein Transmission.The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration.Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
P2860
Q24306217-13A401ED-0CC6-4EB8-8712-70611368C1D2Q24312185-5F0CB12F-2A1B-4B95-A85E-BD01DCC029CFQ26827605-E4C4C0DC-8C96-4711-A193-8B27305C3EDAQ27009984-9778D6B9-D9C0-4924-8220-439DED21165EQ28117589-54C22129-85E0-45CB-B10C-56F6F5BE587EQ28279273-B876446B-F381-4E51-9AB8-FF1D1ADFA639Q28386548-60379FAC-FDB0-4532-8720-B1C205BA57BFQ33366459-3534CD30-2197-4050-BA64-DDAA80CB7518Q33607803-933DC33A-11D1-496F-B5B3-79B253BB13DFQ33613123-98BBF509-36E2-486B-9BA8-8784CE5A8018Q33865366-BEB88E89-2EFC-4B81-B0A7-4BB541B07384Q33898316-C064D4D0-72E8-430B-9FE3-43DE3804D889Q33996828-7DA7CB2D-9E76-42E9-B691-350F74C6B812Q34020626-8074E076-E963-48B7-9901-9F6358109C74Q34098005-38663ADC-8D0B-4D09-89FF-4B359ADBFCBBQ34243731-21E643DF-2A09-40A9-AC82-3AC86C370018Q34596893-B2F434AA-0E80-40F9-B7BC-12FF304F0411Q35094028-63CBE282-FD70-498D-A75C-907D9FA7BA61Q35328089-E028D876-3EAD-4B52-A394-71BE2FAA0BB9Q35941717-590D172F-500F-4CDD-9F18-B8336AA9FF82Q36272936-F749EECB-EB2D-490E-A764-37ADC52BFE20Q36339785-4146DF0B-0B42-4CD2-91B7-662A83BE462EQ36608855-490029A5-9B62-436C-B80C-B42036AF5604Q37070916-3CC54954-BE9A-4D26-8CCF-751692A57CB6Q37306581-84C003ED-A3DC-4E48-BE2D-F8EB882F62F6Q37337494-315AAEFE-5153-441E-B8AA-07311DD498AEQ37349958-D87C2498-79A4-4F91-BC5B-2232EA9B80D2Q37586721-50E2927D-4A14-4FA4-9554-B1991A69BED1Q37741285-F08BFF3E-A7E7-4857-B3A8-29F0F5A35327Q38020536-7EE03E37-2FA5-4B3E-A632-E1BEDBC70F52Q38039084-5B8DD2AD-D56E-44FC-995F-5E7B11979D73Q38275171-8F5C69F7-F675-4711-815C-4B6EF29D0613Q38610515-28117293-8E4B-4CA0-A509-ED25609A3146Q38809645-31AB0A0B-E6F4-4C29-92BC-BE14167F2513Q38825843-7EBB4C1D-92A9-4203-87AB-1CE1E87C6C5AQ38859501-652ADCD1-0154-491B-8FF3-2075030E3C3AQ38896297-45C09275-85DC-45F5-887A-47DC7323E155Q39152836-D86E3485-6E72-46E4-84B6-B6E9010F23B5Q39348762-4D89449A-C4F5-44FC-8EF7-081BBDBE810BQ40150743-CA69E988-8794-41ED-ACF1-AE32B3430573
P2860
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Statins reduce neuronal alpha- ...... models of Parkinson's disease.
@en
type
label
Statins reduce neuronal alpha- ...... models of Parkinson's disease.
@en
prefLabel
Statins reduce neuronal alpha- ...... models of Parkinson's disease.
@en
P2093
P2860
P1476
Statins reduce neuronal alpha- ...... models of Parkinson's disease.
@en
P2093
Andrew O Koob
Anthony Adame
Brian Spencer
Hideya Mizuno
Leslie Crews
Pazit Bar-On
P2860
P304
P356
10.1111/J.1471-4159.2008.05254.X
P407
P577
2008-01-28T00:00:00Z